Laura Bukavina: The use of TMT for localized bladder cancer in octogenarians
Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology and Associate Editor of European Urology, posted the following on X:
“The use of TMT for localized bladder cancer in octogenarians has surged from 53.5% in 2004 to 82.2% in 2021. However, cancer-specific mortality (CSM) higher with TMT compared to RC (50.1% vs 31.1%), with TMT independently predicting a 1.7-fold increased CSM risk.”
Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer
Authors: Mattia Longoni, Francesco Di Bello, Natali Rodriguez Peñaranda, Fabian Falkenbach, Andrea Marmiroli, Quynh Chi Le, Zhe Tian, Jordan A. Goyal, Nicola Longo, Salvatore Micali, Markus Graefen, Gennaro Musi, Felix K. H. Chun, Fred Saad, Shahrokh F. Shariat, Marco Moschini, Giorgio Gandaglia, Francesco Montorsi, Alberto Briganti, Pierre I. Karakiewicz
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023